Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pozen Migraine Combo “Not Approvable”; Imitrex Combo Could Be Affected

Executive Summary

FDA's "not approvable" letter for Pozen's naproxen/ metoclopramide migraine combination MT-100 may prompt the company to revisit the Phase III trial design for an Imitrex combo under development with GlaxoSmithKline
Advertisement

Related Content

Pozen migraine combo to get committee review
Pozen migraine combo to get committee review
Pozen creates program management exec position
Pozen creates program management exec position
GSK migraine combo is Trexima
Advertisement
UsernamePublicRestriction

Register

PS044131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel